Allergy Therapeutics (GB:AGY) has released an update.
Allergy Therapeutics has begun a groundbreaking Phase III trial for its Grass MATA MPL immunotherapy in children, aiming to tackle grass pollen allergies with a short-course treatment. This follows successful trials in adults, where the therapy showed significant improvement over placebo. Results from this long-term study are anticipated by late 2025, potentially offering a transformative solution for pediatric allergy sufferers.
For further insights into GB:AGY stock, check out TipRanks’ Stock Analysis page.
